IM
IMCR.US Immunocore Holdings Ltd
- Market cap
- USD 1.55B
- P/E
- -
- P/B
- 3.69x
- ROE
- -0.7%
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2026.
Is IMCR.US undervalued?
Graham numberThe Graham number of Immunocore Holdings Ltd cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Immunocore Holdings Ltd fundamental analysis
No fundamental analysis for Immunocore Holdings Ltd yet.
Immunocore Holdings Ltd stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Immunocore Holdings Ltd
Immunocore Holdings plc, together with its subsidiaries, engages in the development and commercialization of immunomodulating medicines for patients with cancer, infectious diseases, and autoimmune disease in the United States, Europe, and internationally. The company offers KIMMTRAK for the treatment of unresectable or metastatic uveal melanoma. It also develops oncology programs, including tebentafusp which is in Phase 3 clinical trial for the treatment of advanced cutaneo…
Full company profileImmunocore Holdings Ltd financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 3 quarters up to Sep 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
Immunocore Holdings Ltd annual financial statements (USD; K = thousand, M = million, B = billion, T = trillion)
| Item | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||||
| Revenue | 16.5M | 14.4M | 23.7M | 25.7M | 30.1M | 27.0M | 144M | 197M | 310M | 400M | 433M |
| Gross Profit | 16.5M | 14.4M | 23.7M | -74.3M | -44.7M | 27.0M | 139M | 197M | 304M | 392M | 430M |
| Operating Income | -32.5M | -67.5M | -93.5M | -118M | -86.2M | -129M | -42.8M | -47.2M | -70.5M | -45.4M | -12.4M |
| EBITDA | -29.7M | -64.3M | -86.7M | -109M | -79.6M | -124M | -38.4M | -40.9M | -47.1M | 520K | 13.6M |
| Net Income | -23.1M | -49.6M | -71.6M | -104M | -74.1M | -133M | -43.5M | -43.8M | -51.1M | -35.5M | -2.75M |
| EPS | -9.44 | -20 | -2.62 | -3.81 | -2.33 | -3.04 | -0.95 | -0.89 | -1.02 | -0.71 | -0.05 |
| Balance Sheet | |||||||||||
| Total Assets | 219M | 198M | 196M | 246M | 197M | 407M | 527M | 597M | 1.01B | 1.07B | 1.13B |
| Total Liabilities | 44.1M | 60.5M | 139M | 226M | 142M | 176M | 188M | 228M | 649M | 686M | 710M |
| Shareholders' Equity | 175M | 138M | 56.6M | 19.6M | 55.3M | 232M | 339M | 369M | 361M | 381M | 420M |
| Cash & Short-term Investments | 177M | 119M | 124M | 98.0M | 177M | 321M | 402M | 443M | 820M | 864M | 901M |
| Total Debt | - | 17.2M | 18.9M | 78.7M | 74.5M | 86.2M | 81.4M | 84.0M | 433M | 437M | 436M |
| Cash Flow | |||||||||||
| Operating Cash Flow | -36.9M | -61.7M | -16.6M | -101M | -60.6M | -143M | -49.2M | 2.33M | 26.1M | -10.7M | 1.15M |
| Capital Expenditure | 6.18M | 17.7M | 3.54M | 4.28M | 3.07M | 1.39M | 2.20M | 4.29M | 5.17M | 4.34M | 6.55M |
| Free Cash Flow | -43.1M | -79.5M | -20.2M | -106M | -63.6M | -144M | -51.4M | -1.97M | 20.9M | -15.1M | -5.40M |
| Ratios | |||||||||||
| ROE | -13.2% | -36.0% | -126.6% | -531.1% | -133.9% | -57.6% | -12.8% | -11.9% | -14.2% | -9.3% | -0.7% |
| ROA | -10.6% | -25.0% | -36.6% | -42.3% | -37.6% | -32.8% | -8.3% | -7.3% | -5.1% | -3.3% | -0.2% |
| Net Profit Margin | -140.5% | -343.1% | -302.8% | -404.9% | -246.0% | -493.4% | -30.1% | -22.2% | -16.5% | -8.9% | -0.6% |
| Debt to Equity | - | 0.12x | 0.33x | 4.02x | 1.35x | 0.37x | 0.24x | 0.23x | 1.20x | 1.15x | 1.04x |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
- Debt to Equity
- Total debt divided by shareholders' equity.
Immunocore Holdings Ltd dividends
Immunocore Holdings Ltd has not paid dividends in the last 9 fiscal years.
Who owns Immunocore Holdings Ltd
- Insiders 0.62%
- Institutions 99.38%
- Public & others 0.00%
- Shares outstanding 51.7M
- Free float 46.0M
Top funds holding IMCR.US
| Holder | Shares | % of shares | Change | As of |
|---|---|---|---|---|
| Vanguard Health Care Inv | 4.25M | 8.22% | 0.00% | Sep 2026 |
| Vanguard Capital Opportunity Inv | 2.34M | 4.52% | 0.00% | Sep 2026 |
| PRIMECAP Odyssey Aggressive Growth | 1.11M | 2.15% | -0.14% | Sep 2026 |
| Fidelity Growth Company Fund | 636K | 1.23% | -25.77% | Aug 2026 |
| Fidelity Select Health Care | 500K | 0.97% | 0.00% | Aug 2026 |
| BlackRock Health Sciences Term Trust | 359K | 0.69% | +864.72% | Jun 2026 |
| iShares Biotechnology ETF | 353K | 0.68% | -0.19% | Oct 2026 |
| T. Rowe Price Health Sciences | 340K | 0.66% | -36.71% | Sep 2026 |
| MFS New Discovery I | 304K | 0.59% | 0.00% | Sep 2026 |
| Fidelity Select Biotechnology | 287K | 0.56% | 0.00% | Aug 2026 |
| Belfius Equities Cure C Cap | 270K | 0.52% | 0.00% | Apr 2026 |
| Fidelity Advisor Health Care I | 260K | 0.50% | 0.00% | Sep 2026 |
| Undly L&G Future World UK Eq Idx Fd | 235K | 0.45% | +3.97% | Sep 2026 |
| BlackRock Health Sciences Opps Inv A | 189K | 0.37% | 0.00% | Sep 2026 |
| Wellington Global Hlthcr Eq USD G Ac | 178K | 0.34% | 0.00% | Sep 2026 |
| Principal SmallCap R5 | 172K | 0.33% | -3.54% | Sep 2026 |
| Fidelity Growth Company K6 | 165K | 0.32% | -30.39% | Aug 2026 |
| Old Westbury Small & Mid Cap Strategies | 160K | 0.31% | +350.42% | Jul 2026 |
| Fidelity Capital Appreciation | 159K | 0.31% | 0.00% | Sep 2026 |
| Rhenman Healthcare Equity L/S RC2 SEK | 153K | 0.30% | 0.00% | Jan 2026 |
Top institutions holding IMCR.US
| Holder | Shares | % of shares | Change | As of |
|---|---|---|---|---|
| Wellington Management Company LLP | 5.72M | 11.07% | +21.58% | Jun 2026 |
| RTW INVESTMENTS, LLC | 4.87M | 9.42% | 0.00% | Jun 2026 |
| FMR Inc | 4.31M | 8.33% | -10.81% | Jun 2026 |
| PRIMECAP Management Company | 3.64M | 7.04% | -0.07% | Sep 2026 |
| Bellevue Group AG | 2.79M | 5.40% | -0.31% | Jun 2026 |
| TANG CAPITAL MANAGEMENT LLC | 2.65M | 5.13% | 0.00% | Jun 2026 |
| Acadian Asset Management LLC | 1.82M | 3.53% | +50.79% | Sep 2026 |
| Vestal Point Capital LP | 1.80M | 3.48% | -34.94% | Jun 2026 |
| Two Sigma Investments LLC | 1.65M | 3.19% | +61.46% | Jun 2026 |
| Millennium Management LLC | 1.60M | 3.09% | +29.06% | Jun 2026 |
| Armistice Capital, LLC | 1.43M | 2.76% | +20.20% | Jun 2026 |
| Caligan Partners LP | 1.38M | 2.67% | 0.00% | Jun 2026 |
| Kynam Capital Management, LP | 1.38M | 2.66% | +55.38% | Jun 2026 |
| Bvf Inc | 1.29M | 2.50% | 0.00% | Jun 2026 |
| Trails Edge Capital Partners, LP | 1.06M | 2.06% | +55.76% | Jun 2026 |
| BlackRock Inc | 1.00M | 1.94% | +53.07% | Jun 2026 |
| Point72 Asset Management, L.P. | 990K | 1.92% | -10.16% | Jun 2026 |
| T. Rowe Price Associates, Inc. | 831K | 1.61% | -9.60% | Jun 2026 |
| Jupiter Topco LLC | 709K | 1.37% | 0.00% | Jun 2026 |
| CANTOR FITZGERALD, L. P. | 680K | 1.32% | +171.85% | Jun 2026 |
Immunocore Holdings Ltd company profile
- Company name
- Immunocore Holdings Ltd
- Ticker
- IMCR.US
- Exchange
- USA Stocks
- Listed since
- Feb 5, 2021
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 524
- Fiscal year end
- December
- Address
- 92 Park Drive, Abingdon, United Kingdom, OX14 4RY
- Phone
- 44 12 3543 8600
- Website
- immunocore.com
About Immunocore Holdings Ltd
Immunocore Holdings plc, together with its subsidiaries, engages in the development and commercialization of immunomodulating medicines for patients with cancer, infectious diseases, and autoimmune disease in the United States, Europe, and internationally. The company offers KIMMTRAK for the treatment of unresectable or metastatic uveal melanoma. It also develops oncology programs, including tebentafusp which is in Phase 3 clinical trial for the treatment of advanced cutaneous melanoma and adjuvant uveal melanoma; brenetafusp which is in Phase 3 clinical trial for the treatment of first-line advanced cutaneous melanoma and in Phase 1/2 clinical trial for the treatment of various tumor types; IMC-R117C which is in Phase 1/2 clinical trial for the treatment of advanced solid tumors, such as colorectal cancer; and IMC-P115C which is in Phase 1 clinical trial for patients with tumors that express PRAME. In addition, the company is involved in the development of IMC-M113V which is in Phase 1 clinical trial for a potential functional cure of human immunodeficiency virus; and IMC-I109V which is in Phase 1 clinical trial for a potential functional cure of hepatitis B virus. Further, it develops IMC-S118AI which is in pre-investigation stage for the treatment of type 1 diabetes; and IMC-U120AI which is in pre-investigation stage for the treatment of atopic dermatitis. The company was founded in 1999 and is headquartered in Abingdon, the United Kingdom.
Immunocore Holdings Ltd management
10- Dr. Bahija Jallal Ph.D.CEO & Executive Director · born 1961
- Mr. Travis Alan Coy M.B.A.CFO, Executive VP & Head of Corporate Development · born 1980
- Dr. Kripa Ram Ph.D.Executive VP & Chief Operating Officer · born 1963
- Mr. John Goll IIISVP, Finance & Chief Accounting Officer
- Ms. Annelise Vuidepot Ph.D.Chief Science and Technology Officer & Milton Park Site Head
- Mr. Sean D. BuckleyVP & Chief Information Officer · born 1983
- Mr. Ryan BakerVice President of Investor Relations
- Ms. Lily Margaret HepworthExecutive VP, General Counsel & Company Secretary · born 1983
- Ms. Elizabeth Varki Jobes Esq., J.D.Chief Compliance Officer · born 1967
- Mr. Sébastien DesprezVice President of Communications